Tivozanib hydrochloride hydrate

SKU: orb1686536

Description

Tivozanib hydrochloride hydrate (AV-951) is a potent and selective oral inhibitor targeting VEGFR-1, -2, and -3 tyrosine kinases. It is widely used in preclinical research to study angiogenesis, tumor growth, and metastasis in both cellular assays and animal models.

Research Area

Cardiovascular Research, Signal Transduction

Key Properties

• CAS Number: 682745-41-1
• MW: 509.34
• Purity: 99.99%
• Formula: C₂₂H₂₂Cl₂N₄O₆
• SMILES: O.Cl.COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
• Target: VEGFR
• Solubility: DMSO:100 mg/mL (196.33 mM)

Bioactivity

• Target IC50:
  VEGFR2:6.5 nM|VEGFR3:15 nM|VEGFR1:30 nM
• In Vivo:
  In the Calu-6 tumor-bearing athymic mice model, Tivozanib hydrochloride hydrate (0.04-1 mg/kg/day; orally, for 14-21 days) inhibits tumor growth, angiogenesis, and vascular permeability.
• In Vitro:
  Tivozanib hydrochloride hydrate (0-100 nM; 24 hours) inhibited the proliferation of HUVEC cells.

Storage & Handling

• Storage: keep away from direct sunlight,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

AV-951 hydrochloride hydrate, KRN951 hydrochloride hydrate, VEGFR

Compound Identifiers

PubChem CID

11547978